Results presented at the 2014 World Transplant Congress evaluated the safety and efficacy of CSL Behring's C1 Inhibitor (C1-INH) concentrate in preventing antibody-mediated rejection following kidney transplants in highly sensitized patients.
C1-INH is a human protein and an important inhibitor of the complement system. Antibody-mediated rejection is a major cause of kidney transplant failure and a prime barrier to improving long-term outcomes for transplant patients. The types of antibody-mediated rejection vary in acuity and severity. Approximately 10 to 15 percent of kidney recipients experience rejection within one year after transplantation.
The placebo-controlled, single-center study evaluated 20 highly sensitized patients, meaning they already had antibodies against donor organs. Subjects were randomized to receive either placebo or 20 IU/kg of C1-INH, administered intra-operatively, then twice a week for seven additional doses. Patients were desensitized with immunoglobulin and rituximab, decreasing the patient's antibody levels prior to transplant.
The study found that post-transplant treatment with C1-INH results in significant increases in the levels of complement components 3 and 4, suggesting that C1-INH inhibits activation of the complement system following transplantation. Antibody-mediated rejection is a major cause of kidney transplant failure and is often associated with activation of complement, a set of proteins that work with antibodies and play a role in the development of inflammation and tissue damage.
According to study findings, fewer patients who were administered C1-INH developed serious adverse events compared to those administered placebo (20 percent versus 30 percent). C1-INH function and antigen levels in blood increased with C1-INH treatment [C1 function (p=0.0007) and C1-INH antigen percent (p=0.013)]. Patients treated with C1-INH experienced increased C3 levels on day 30 (p=0.005), while C4 levels were significantly higher at all time points.
During the study period, no patient treated with C1-INH developed antibody-mediated rejection. Twenty percent of patients developed antibody-mediated rejection following the study period. Thirty percent of patients treated with placebo developed antibody-mediated rejection, ten percent during the study period.
"Antibody-mediated rejection is a severe form of rejection that can occur in patients who have undergone a kidney transplant," said Stanley C. Jordan, M.D., Kidney Transplant, Cedars-Sinai Medical Center in Los Angeles, and one of the study's investigators. "Our findings provide additional insight into how C1-INH affects complement activation and represent an important advance in the study of complement-targeting therapeutics."
This Investigator-Initiated Research study was supported by CSL Behring.
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- USDA Microbiologist Warns Bacteria In Vaping Products May Be A Health Concern
- Kudos To "The Independent" Newspaper For Debunking Nibiru "Blood Moon" Hoax
- Free Market Validation: Men With Hair Transplants Are Seen As Younger, More Attractive
- Sudden Death In Hypertrophic Cardiomyopathy - The Exercise Didn't Do It
- Your Microbiome Did Not Cause Your Weight Problem
- A Great Blitz Game
- Control Cancer By Making The Tumor Cell Environment Hostile
- "You have a point. Let me find out how this got misconstrued...."
- "So what's your excuse? Try googling the actual study abstract, it's called 'Bacterial Populations..."
- "It seems to me to be the ultimate in irony to commit suicide now, because of the belief that in..."
- "The image problem with the vaping community is that proponents smack of zealotry. This is a great..."
- "Sigh. Not only is it common sense to wash out your drinking cup/a vaping device tip, my own dental..."
- How Herpes Drugs Work
- The Infrared Sauna: Hollywood's Hot, Pricey 'Magic' Box
- E-Cigarette Flavors, Biotech Courts And More Media Links
- <a href="/news/2016/08/29/pediatricians-crack-down-anti-vaxx-parents-policy-report-says-9930">Pediatricians To Crack Down On Anti-Vaxx Parents, Policy Report Says <i class="fa fa-angle-double-right"></i></a>
- <a href="/news/2016/08/29/high-drug-costs-blame-playa-or-play-9873">High Drug Costs - Blame The Playa Or The Play? <i class="fa fa-angle-double-right"></i></a>
- <a href="/node/9873">High Drug Costs - Blame The Playa Or The Play? <i class="fa fa-angle-double-right"></i></a>
- Researchers identify characteristic chemical signature for chronic fatigue syndrome
- Isotope study determines fish were more prominent in early Alaskans' diets
- Tiny changes in Parkinson's protein can have 'dramatic' impact on processes behind onset
- Climate change has less impact on drought than previously expected
- Five-year study reveals patients operated on at night twice as likely to die as patients who have daytime operations